Landry Robert E has filed 87 insider transactions across 3 companies since February 2023.
Most recent transaction: a grant/award of 7700 shares of Zymeworks Inc. ($ZYME) on January 12, 2026.
Activity breakdown: 0 open-market purchases and 32 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Landry Robert E | Not found | A | Restricted Stock Unit | 7700 | $0.00 | 7,700.0000 | 75,775,214 | 9999.99% | 0.01% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Landry Robert E | Not found | A | Stock Option (Right to Buy) | 11500 | $0.00 | 11,500.0000 | 75,775,214 | 9999.99% | 0.02% |
| Aug. 11, 2025 | Zymeworks Inc. | $ZYME | Landry Robert E | Not found | A | Stock Option (Right to Buy) | 62000 | $0.00 | 62,000.0000 | 75,878,738 | 9999.99% | 0.08% |
| May 14, 2025 | CYTOKINETICS INC | $CYTK | Landry Robert E | Director | A | Common Stock | 7333 | $0.00 | 7,333.0000 | 118,410,689 | 9999.99% | 0.01% |
| May 14, 2025 | CYTOKINETICS INC | $CYTK | Landry Robert E | Director | A | Non-Qualified Stock Option (Right to Buy) | 10880 | $0.00 | 10,880.0000 | 118,410,689 | 9999.99% | 0.01% |
| Feb. 10, 2025 | CYTOKINETICS INC | $CYTK | Landry Robert E | Director | A | Non-Qualified Stock Option (Right to Buy) | 25538 | $0.00 | 25,538.0000 | 0 | 9999.99% | 0.00% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 400 | $0.00 | 11,787.0000 | 133,100,000 | 3.28% | 0.00% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 281 | $956.65 | 23,963.0000 | 133,100,000 | 1.16% | 0.00% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 400 | $378.98 | 24,244.0000 | 133,100,000 | 1.68% | 0.00% |
| Jan. 31, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 400 | $0.00 | 12,187.0000 | 133,100,000 | 3.18% | 0.00% |
| Jan. 31, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 400 | $378.98 | 24,126.0000 | 133,100,000 | 1.69% | 0.00% |
| Jan. 31, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 282 | $953.42 | 23,844.0000 | 133,100,000 | 1.17% | 0.00% |
| Jan. 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 500 | $378.98 | 24,078.0000 | 133,100,000 | 2.12% | 0.00% |
| Jan. 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 352 | $951.26 | 23,726.0000 | 133,100,000 | 1.46% | 0.00% |
| Jan. 23, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 1100 | $0.00 | 13,087.0000 | 133,100,000 | 7.75% | 0.00% |
| Jan. 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 500 | $0.00 | 12,587.0000 | 133,100,000 | 3.82% | 0.00% |
| Jan. 23, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 1100 | $378.98 | 24,354.0000 | 133,100,000 | 4.73% | 0.00% |
| Jan. 23, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 776 | $948.50 | 23,578.0000 | 133,100,000 | 3.19% | 0.00% |
| Jan. 17, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 500 | $0.00 | 14,187.0000 | 133,100,000 | 3.40% | 0.00% |
| Jan. 17, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 500 | $378.98 | 23,608.0000 | 133,100,000 | 2.16% | 0.00% |
| Jan. 17, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 354 | $932.34 | 23,254.0000 | 133,100,000 | 1.50% | 0.00% |
| Jan. 12, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 800 | $0.00 | 14,687.0000 | 133,100,000 | 5.17% | 0.00% |
| Jan. 12, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 800 | $378.98 | 23,676.0000 | 133,100,000 | 3.50% | 0.00% |
| Jan. 12, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 568 | $928.18 | 23,108.0000 | 133,100,000 | 2.40% | 0.00% |
| Jan. 4, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 500 | $0.00 | 15,487.0000 | 133,100,000 | 3.13% | 0.00% |
| Jan. 4, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 342 | $917.05 | 22,876.0000 | 133,100,000 | 1.47% | 0.00% |
| Jan. 4, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 500 | $378.98 | 23,218.0000 | 133,100,000 | 2.20% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 1100 | $378.98 | 23,406.0000 | 133,100,000 | 4.93% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 688 | $912.30 | 22,718.0000 | 133,100,000 | 2.94% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 650 | $0.00 | 17,087.0000 | 133,100,000 | 3.66% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 1100 | $0.00 | 15,987.0000 | 133,100,000 | 6.44% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 650 | $378.98 | 22,727.0000 | 133,100,000 | 2.94% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 421 | $888.34 | 22,306.0000 | 133,100,000 | 1.85% | 0.00% |
| Dec. 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 850 | $378.98 | 22,689.0000 | 130,400,000 | 3.89% | 0.00% |
| Dec. 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 612 | $884.88 | 22,077.0000 | 130,400,000 | 2.70% | 0.00% |
| Dec. 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 750 | $0.00 | 18,587.0000 | 130,400,000 | 3.88% | 0.00% |
| Dec. 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 850 | $0.00 | 17,737.0000 | 130,400,000 | 4.57% | 0.00% |
| Dec. 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 750 | $378.98 | 22,381.0000 | 130,400,000 | 3.47% | 0.00% |
| Dec. 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 542 | $872.21 | 21,839.0000 | 130,400,000 | 2.42% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 723 | $871.12 | 21,631.0000 | 130,400,000 | 3.23% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 1000 | $0.00 | 19,337.0000 | 130,400,000 | 4.92% | 0.00% |
| Dec. 12, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 6381 | $856.71 | 21,354.0000 | 130,400,000 | 23.01% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 1000 | $378.98 | 22,354.0000 | 130,400,000 | 4.68% | 0.00% |
| Dec. 11, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 2552 | $844.09 | 27,735.0000 | 130,400,000 | 8.43% | 0.00% |
| Dec. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 1013 | $843.79 | 30,956.0000 | 130,400,000 | 3.17% | 0.00% |
| Dec. 11, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 669 | $844.09 | 30,287.0000 | 130,400,000 | 2.16% | 0.00% |
| Aug. 23, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 223 | $844.00 | 31,969.0000 | 130,400,000 | 0.69% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 3000 | $378.98 | 35,566.0000 | 130,400,000 | 9.21% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 2204 | $825.17 | 33,362.0000 | 130,400,000 | 6.20% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 39 | $819.47 | 33,323.0000 | 130,400,000 | 0.12% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 50 | $820.46 | 33,273.0000 | 130,400,000 | 0.15% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 48 | $821.39 | 33,225.0000 | 130,400,000 | 0.14% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 18 | $822.57 | 33,207.0000 | 130,400,000 | 0.05% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 4 | $824.30 | 33,203.0000 | 130,400,000 | 0.01% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 13 | $825.59 | 33,190.0000 | 130,400,000 | 0.04% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 4 | $829.16 | 33,186.0000 | 130,400,000 | 0.01% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 589 | $825.17 | 32,566.0000 | 130,400,000 | 1.78% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 10 | $818.81 | 33,169.0000 | 130,400,000 | 0.03% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 115 | $820.85 | 33,054.0000 | 130,400,000 | 0.35% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 142 | $821.40 | 32,912.0000 | 130,400,000 | 0.43% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 128 | $822.67 | 32,784.0000 | 130,400,000 | 0.39% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 181 | $823.60 | 32,603.0000 | 130,400,000 | 0.55% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 157 | $824.54 | 32,446.0000 | 130,400,000 | 0.48% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 243 | $825.37 | 32,203.0000 | 130,400,000 | 0.75% | 0.00% |
| March 28, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 31 | $826.36 | 32,172.0000 | 130,400,000 | 0.10% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 3000 | $0.00 | 20,337.0000 | 130,400,000 | 12.86% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 800 | $0.00 | 0.0000 | 130,400,000 | 100.00% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 7 | $830.01 | 33,179.0000 | 130,400,000 | 0.02% | 0.00% |
| March 27, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 800 | $381.92 | 33,155.0000 | 130,400,000 | 2.47% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | F | Common Stock | 2248 | $774.29 | 33,107.0000 | 130,400,000 | 6.36% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 51 | $783.05 | 33,056.0000 | 130,400,000 | 0.15% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 113 | $784.27 | 32,943.0000 | 130,400,000 | 0.34% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 78 | $785.88 | 32,865.0000 | 130,400,000 | 0.24% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 85 | $786.45 | 32,780.0000 | 130,400,000 | 0.26% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 58 | $787.47 | 32,722.0000 | 130,400,000 | 0.18% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 99 | $788.62 | 32,623.0000 | 130,400,000 | 0.30% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 49 | $789.05 | 32,574.0000 | 130,400,000 | 0.15% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 10 | $790.41 | 32,564.0000 | 130,400,000 | 0.03% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 3 | $791.00 | 32,561.0000 | 130,400,000 | 0.01% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 2 | $793.33 | 32,559.0000 | 130,400,000 | 0.01% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 99 | $794.61 | 32,460.0000 | 130,400,000 | 0.30% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 59 | $795.41 | 32,401.0000 | 130,400,000 | 0.18% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 18 | $796.43 | 32,383.0000 | 130,400,000 | 0.06% | 0.00% |
| Feb. 6, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 28 | $797.43 | 32,355.0000 | 130,400,000 | 0.09% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Non-Qualified Stock Option (right to buy) | 3000 | $0.00 | 800.0000 | 130,400,000 | 78.95% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | S | Common Stock | 739 | $764.50 | 32,355.0000 | 130,400,000 | 2.23% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Landry Robert E | EVP Finance CFO | M | Common Stock | 3000 | $381.92 | 35,355.0000 | 130,400,000 | 9.27% | 0.00% |